Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 367

Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium

Dr Jo Caers speaks to ecancer at the 2019 International Myeloma Workshop meeting in Boston about real-world use of carfilzomib in relapsed myeloma patients, focusing on patients with existing cardiovascular medical histories.

He explains that myeloma patients are more likely to have cardiovascular complications due to both their disease and the treatment options for their disease, which is why this study focused on these patients.

Dr Caers reports that these patients generally responded as well as patients who did not have pre-existing cardiovascular comorbidities. While this patient group experienced more side effects, they were manageable.

However, Dr Caers still stresses the importance of monitoring cardiac health during treatment of these patients.


Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation